Hofseth BioCare ASA
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hofseth BioCare ASA (HOFBF) is a Norway-based biotechnology company founded in 2000 and headquartered in Ålesund that develops, manufactures, markets and sells high-value marine-derived ingredients and finished products for human nutrition, pet nutrition and animal feed from fresh Norwegian salmon off-cuts using proprietary enzymatic hydrolysis technology. Core products include OmeGo fresh salmon oil providing a full spectrum of omega fatty acids including EPA, DHA and DPA; ProGo bioactive salmon protein hydrolysate peptides supporting metabolic health, sports performance, recovery, healthy aging, antioxidant activity and vitality; CalGo natural marine calcium bone powder for bone and joint health; CollaGo collagen peptide powder optimized for hair, skin and nail beauty; PetGo non-soluble salmon protein for pet nutrition; and Brilliant Petcare premium pet nutrition brand products. The company operates globally with primary revenue from Europe, followed by North America and Asia, through offices and branches in Oslo, Chicago, Mumbai, Tokyo, Menlo Park, London, Zürich and New Jersey, serving nutraceutical, supplement, sports nutrition, health food and pet markets. Recent developments include a February 2025 strategic partnership with Symrise to expand the Berkåk facility, tripling group manufacturing capacity for human health and pet nutrition products; a contemplated October 2025 private placement to fund B2B growth in Asia and the US, metabolic health initiatives including GLP-1 support and healthy aging following a 2025 NutraIngredients-USA award, Brilliant Petcare expansion and R&D; and a November 2025 strategic product partnership with James LaValle and Metabolic Elite.
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2026
Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M
Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas
Hofseth BioCare ASA: HBC ANNUAL REPORT 2025
Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT
Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION
Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING
Hofseth BioCare ASA: Extraordinary General Meeting completed
Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING
Hofseth BioCare ASA: HBC ANNOUNCES STRATEGIC PRODUCT PARTNERSHIP WITH JAMES LAVALLE & METABOLIC ELITE
Hofseth BioCare ASA: Publication of the Prospectus – Start of the Subscription Period for the Subsequent Offering
Hofseth BioCare ASA: Terms of the Subsequent Offering
Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
Hofseth BioCare ASA: Mandatory Notification of Trade
Hofseth BioCare ASA: Key Information Relating to Subsequent Offering
Hofseth BioCare ASA: Disclosures of Large Shareholdings
Hofseth BioCare ASA: Private placement successfully placed
Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio
Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio
Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER